Thor Medical begins equipment installation at alphaone plant

Thor Medical announced it has started equipment installation at its AlphaOne plant in Herøya Industrial Park, Norway. This first commercial-scale isotope production facility will supply alpha-emitters for precision cancer treatment. The company has taken over the new laboratory infrastructure and installed large tanks for thorium raw material storage, a key milestone in building the plant's core production.

Chief executive Jasper C. Kurth highlighted that this advancement is crucial for enabling global radiopharmaceutical pipelines and laying the groundwork for pharmaceutical partners to advance clinical programs and bring transformative cancer therapies worldwide. Construction on the building infrastructure will continue through the first half of 2026, alongside the installation of processing and electrical equipment, instrumentation, and hot cells.

Chief financial officer and chief operating officer Brede Ellingsæter confirmed the project is on track for mechanical completion by Q2 2026 and production start in Q3 2026. AlphaOne is designed to produce 21,000 patient doses initially, expanding to approximately 60,000 doses over ten years. The facility is fully funded, with profitable operations anticipated by late 2027.